Amphastar Pharmaceuticals... (AMPH)
NASDAQ: AMPH
· Real-Time Price · USD
29.19
-0.20 (-0.68%)
At close: Sep 04, 2025, 3:59 PM
29.19
0.00%
After-hours: Sep 04, 2025, 04:11 PM EDT
Amphastar Pharmaceuticals Revenue Breakdown
| Period Ending | Jun 30, 2025 |
|---|---|
| BAQSIMI Revenue | 46.69M |
| BAQSIMI Revenue Growth | n/a |
| Glucagon Revenue | 20.6M |
| Glucagon Revenue Growth | n/a |
| Lidocaine Revenue | 15M |
| Lidocaine Revenue Growth | n/a |
| Other Products Revenue | 53.07M |
| Other Products Revenue Growth | n/a |
| Primatene MIST Revenue | 22.88M |
| Primatene MIST Revenue Growth | n/a |
| Total product revenues, net Revenue | 174.41M |
| Total product revenues, net Revenue Growth | n/a |
| Epinephrine Revenue | 16.18M |
| Epinephrine Revenue Growth | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Jun 30, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Revenue | 299K | 81K | 2.19M | 178K | 1.56M | 403K | 2.36M | 833K | 1.18M | 127K | 2.28M | 719K | 766K | 933K | 1.1M |
| China Revenue Growth | +269.14% | -96.31% | +1132.58% | -88.62% | +288.09% | -82.95% | +183.67% | -29.53% | +830.71% | -94.43% | +216.97% | -6.14% | -17.90% | -14.87% | n/a |
| France Revenue | 7.11M | 7.86M | 9.24M | 4.52M | 4.41M | 1.78M | 459K | 1.67M | 635K | 1.94M | 1.59M | 1.63M | 1.92M | 2.32M | 52.76M |
| France Revenue Growth | -9.47% | -14.96% | +104.31% | +2.54% | +148.31% | +286.93% | -72.47% | +162.52% | -67.22% | +21.75% | -2.39% | -14.88% | -17.49% | -95.60% | n/a |
| United States Revenue | 167M | 162.59M | 175.09M | 186.51M | 176.42M | 169.66M | 175.28M | 178.06M | 143.9M | 137.96M | 131.15M | 117.78M | 120.79M | 117.11M | n/a |
| United States Revenue Growth | +2.71% | -7.14% | -6.13% | +5.72% | +3.99% | -3.21% | -1.56% | +23.74% | +4.30% | +5.19% | +11.35% | -2.49% | +3.14% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 24.23M | 27.86M | 23.36M | 23.82M | 22.3M | 25.05M | 21.74M | 19.06M | 19M | 20.59M | 16.1M | 16.77M | 15.73M | 17.99M | 14.7M | 15.65M | 18.69M | 19.88M | 15.82M | 15.35M | 19.95M | 14.04M | 13.98M | 14.24M | 15.42M | 19.47M | 16.41M | 15.37M | 13.54M | 12.72M | 10.85M | 13.42M | 13.83M | 12.82M | 12.19M | 12.09M | 10.79M | 12.22M | 10.02M | 10.21M | 12.78M | 13.97M |
| Selling, General, and Administrative Revenue Growth | -13.05% | +19.26% | -1.91% | +6.81% | -10.98% | +15.22% | +14.04% | +0.33% | -7.74% | +27.90% | -3.98% | +6.56% | -12.53% | +22.41% | -6.13% | -16.26% | -5.94% | +25.63% | +3.08% | -23.07% | +42.09% | +0.42% | -1.83% | -7.63% | -20.80% | +18.63% | +6.77% | +13.47% | +6.49% | +17.23% | -19.16% | -2.96% | +7.90% | +5.11% | +0.84% | +12.07% | -11.72% | +22.00% | -1.83% | -20.14% | -8.55% | n/a |
| Research and Development Revenue | 20.08M | 20.1M | 18.14M | 21.08M | 17.65M | 14.23M | 17.85M | 16.66M | 16.84M | 19.82M | 17.24M | 18.51M | 22.8M | 16.22M | 17.29M | 10.76M | 18.12M | 14.77M | 18.13M | 17.64M | 16.15M | 15.3M | 19.64M | 18.61M | 16M | 14.61M | 16.73M | 11.34M | 15.47M | 14.26M | 11.39M | 10.04M | 10.73M | 11.25M | 12.28M | 9.72M | 10.48M | 8.39M | 8.65M | 11.12M | 10.73M | 6.57M |
| Research and Development Revenue Growth | -0.08% | +10.77% | -13.93% | +19.40% | +24.02% | -20.25% | +7.11% | -1.06% | -15.00% | +14.96% | -6.90% | -18.79% | +40.53% | -6.15% | +60.67% | -40.63% | +22.74% | -18.57% | +2.77% | +9.26% | +5.53% | -22.10% | +5.58% | +16.32% | +9.51% | -12.71% | +47.57% | -26.69% | +8.47% | +25.16% | +13.48% | -6.45% | -4.60% | -8.37% | +26.27% | -7.22% | +24.94% | -3.07% | -22.16% | +3.65% | +63.31% | n/a |
| Sales and Marketing Revenue | 10.23M | 11.87M | 10.42M | 8.99M | 9.01M | 9.37M | 8.62M | 6.41M | 6.72M | 7.11M | 5.47M | 4.78M | 5.76M | 5.52M | 4.08M | 4.75M | 4.13M | 4.54M | 3.79M | 3.67M | 4.03M | 3.29M | 3.48M | 3.22M | 2.99M | 3.14M | 2.6M | 1.96M | 1.88M | 1.72M | 1.63M | 1.76M | 1.6M | 1.48M | 1.49M | 1.29M | 1.33M | 1.35M | 1.31M | 1.17M | 1.47M | 1.52M |
| Sales and Marketing Revenue Growth | -13.75% | +13.83% | +15.89% | -0.19% | -3.83% | +8.72% | +34.52% | -4.63% | -5.50% | +29.92% | +14.38% | -16.89% | +4.29% | +35.44% | -14.12% | +14.92% | -8.99% | +19.80% | +3.10% | -8.77% | +22.22% | -5.24% | +7.92% | +7.65% | -4.74% | +20.99% | +32.25% | +4.64% | +9.01% | +5.65% | -7.23% | +10.03% | +7.91% | -0.80% | +15.49% | -3.08% | -1.48% | +3.44% | +11.61% | -20.34% | -3.42% | n/a |